Novel Broad-Spectrum Antimicrobial Drug Candidate For Licensing
Peptide-Based – Safe – Very Potent Against Pseudomonas aruginosa
This peptide-based drug candidate was tested for its antimicrobial activity against many microbes. The researchers found that this drug candidate has a broad range of antimicrobial activity and specific capabilities to fight Pseudomonas aeruginosa with low in vitro cytotoxicity and promising potential to express anti-lipopolysaccharide (anti-endotoxin) qualities. Pseudomonas aeruginosa is a notorious bacterium which is often highly resistant to antibiotics and often leads to Sepsis. This drug candidate could be effectively used for Pseudomonas aeruginosa and other microbes. One can envision expanding its properties into an anti-sepsis agent.
The plight of antimicrobial resistance continues to limit the availability of antibiotic treatment effective in combating resistant bacterial infections. Despite efforts made to rectify this issue and minimize its effects on both patients and the wider community, progress in this area remains minimal. This drug candidate addresses this issue. The novel peptide-designed drug candidate was custom designed to exhibit antimicrobial properties by building upon years of research that the Company was involved in. It could be an effective tool to fight infections caused by antibiotic-resistant organisms, particularly infections caused by Pseudomonas aeruginosa.
A patent has been filed for this drug candidate, and a scientific paper in a peer-reviewed journal is in the final phase of review. The Company is planning to apply for IND. The Company’s preferred route is to license it to an experienced pharmaceutical manufacturer to fast-track the process to get this product to the market quicker.